Review Article

Possible cognition changes in women with polycystic ovary syndrome: a narrative review

Marzieh Saei Ghare Naz, DEGREE¹, Fatemeh Alsadat Rahnemaei, DEGREE², Fahimeh Ramezani Tehrani, DEGREE¹, Fatemeh Sayehmiri, DEGREE³, Vida Ghasemi, DEGREE⁴, Mojde Banaei, DEGREE⁵, Giti Ozgoli, PhD⁶

¹Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, ²Reproductive Health Research Center, Department of Obstetrics & Gynecology, Al-zahra Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, ³Faculty of Medicine, ⁴Reproductive Health, Asadabad School of Medical Sciences, Asadabad, ⁵Reproductive Health, School of Nursing and Midwifery, Hormozgan University of Medical Sciences, Bandar Abbas, ⁶Department of Midwifery and Reproductive Health, Midwifery and Reproductive Health Research Center, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Running head:

Received: 2022.06.07.

Revised: 2022.11.15.

Accepted: 2023.05.25.
**Corresponding author:** Giti Ozgoli, PhD

Department of Midwifery and Reproductive Health, Midwifery and Reproductive Health Research Center, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran Province, Tehran Postal code, Iran

E-mail: gozgoli@gmail.com

https://orcid.org/0000-0003-2111-7024
Abstract

Nowadays, polycystic ovary syndrome (PCOS) and cognitive dysfunction are major health problems among female. This narrative review aimed to investigate cognitive dysfunction in female with PCOS. English and Persian articles published in PubMed, Scopus, Web of Science, Google Scholar, PsycINFO, Scientific Information Database, and Cochrane Database of Systematic Reviews until May 2022 were searched. Sixteen studies involving 813 female with PCOS and 1,382 controls were assessed. In these studies, the association between biochemical factors and symptoms of PCOS and memory, attention, executive functioning, information processing speed, and visuospatial skills was evaluated. The literature review revealed the possible cognitive changes in female with PCOS. This study summarized the different aspects of cognitive function in female with PCOS due to medication, psychological problems (mood disorders caused by disease symptoms and complications), and biochemical markers, such as metabolic and sex hormone abnormalities. Considering the existing scientific gap regarding the possibility of cognitive complications in female with PCOS, further biological studies should be conducted to evaluate the potential mechanisms involved.

Keywords: Polycystic ovary syndrome; Cognitive function; Metabolic syndrome; Review
Introduction

Polycystic ovary syndrome (PCOS) is a common health problem among female of childbearing age worldwide [1-3]. Disorders and complications associated with PCOS impose significant psychological and economic burdens on different people in different countries [4-7]. Several studies have indicated various aspects of cognitive dysfunction in patients with PCOS [8-10].

Cognitive functioning refers to multiple mental abilities, including learning, thinking, reasoning, remembering, problem solving, decision making, and attention [11]; dementia is a progressive or long-lasting condition that leads to cognitive changes [12,13]. By 2019, approximately 50 million people had dementia worldwide, with an incidence of new cases every three seconds [14,15]. As a cognitive disorder, dementia is the fifth-leading cause of mortality globally [16]. A study on 70 postmenopausal female with PCOS and 140 control female showed that white matter lesions and silent cerebral infarcts increased in female with PCOS [17]. In another study, PCOS was associated with a remarkable reduction in diffusion along the main axis of white matter fibers and cognitive function was diminished compared to the control group [8].

Cognitive function is strongly related to age [18], Although cognitive impairment is common after menopause, it has been proposed that cardiovascular risk factors during the premenopausal period might adversely affect cognitive function [19]. In line with this study, the results of a study on healthy young female of reproductive age showed a possible association between obesity and cognitive function [20]. The effect of age on the progressive disease course in female with PCOS
is contradictory, and it has been observed that with increasing age in these female, menstrual
cycles become regular because the production of androgens decreases with increasing age [21-
23]. Since female with PCOS are at an increased risk of developing cardiovascular risk factors
before menopause, it has been hypothesized that they may also be at risk of cognitive
dysfunction during the premenopausal period.

As PCOS and cognitive disorders are important health problems worldwide, this study was
conducted as a narrative review to discuss cognitive dysfunction in female with PCOS, which may
pave the way for further extensive research investigating the correlation between the two
conditions.

Method

This narrative review was conducted to survey cognitive function in female with PCOS. Articles
published in PubMed, Scopus, Web of Science, Google Scholar, PsycINFO, the Scientific
Information Database, and the Cochrane Database of Systematic Reviews dated until to May 2022
were searched. There were no time limitations in the search for articles. Articles in English and
Persian were searched using the following keywords and their derivatives: polycystic ovary
syndrome, PCOS, acne, hirsutism, obesity, drug, brain function, insulin resistance, metabolic
syndrome, hormones, dementia, mild cognitive impairment, Alzheimer's disease (AD), cognitive
function, cognitive impairment, cognition, cognitive decline, cognitive health, depression, anxiety, and androgen.

The findings of this study are reported in the subject matter section. This review was based on a standard checklist for quality assessment of narrative review articles [27]. The inclusion criteria were observational and experimental studies and reviews and articles that provided related content and objectives of this review paper. Articles containing duplicate content or those that provided content outside the scope of this study were excluded. To ensure comprehensiveness of the search, the list of references used in the articles was examined. The participants in the included studies were female with PCOS, without age limitations. The outcomes of these studies were measures of cognitive change.

**Results**

This review assessed 16 studies involving 813 female with PCOS and 1,382 controls. In these studies, the associations between biochemical factors and symptoms of PCOS with memory, attention, executive functioning, information processing speed, and visuospatial skills were evaluated. This study summarized the different aspects of cognitive function in female with PCOS due to medication, psychological problems (mood disorders caused by disease symptoms and complications), and biochemical markers such as metabolic and sex hormone abnormalities. Table 1 presents the characteristics of these studies. Fig. 1 shows possible cognitive changes in female with PCOS.
Hormones

Female with PCOS suffer from hormonal disorders such as increased androgen levels, disrupted luteinizing hormone (LH)/follicle stimulating hormone (FSH) ratio, and higher estrogen levels [28]. A recent review has described potential neuroendocrine- and brain-specific mechanisms in the development of PCOS [29]. Research comparing cognitive functions among boys and girls has shown that the cognitive function of girls in the post-ovulation phase is similar to that of boys. In contrast, their cognitive function before the ovulation phase differs from that of boys [30]. Testosterone is a sex hormone that plays an essential role in the cognitive function of both male and female [31]. It has been reported that people with high testosterone levels perform better on 3D mental rotation cognitive tasks [32]. Rees et al. [33] conducted a study on 18 female with PCOS and 18 healthy controls, and found a significant correlation between blood testosterone levels, axial diffusivity (AD) and fractional anisotropy. However, no such correlation was observed in the control group [33]. Through two types of receptors (ERα and ERβ), estrogen has a wide range of functions in different parts of the brain (cortex, hippocampus, hypothalamus, sensory ganglia). Thus, it is effective in improving cognitive and motor functions and emotional states [34]. However, a conflicting study indicated that the levels of different sex hormones during the menstrual cycle were not related to female's cognitive function [35]. In this regard, the results of another study showed that high levels of progesterone were associated with increased amygdala reactions and higher levels of emotional memory [36]. In fact, during the luteal phase, an
increased response of the amygdala to negative emotional stimuli was observed in this study [36].

The amygdala plays an important role in cognitive function [37].

In a study of 135 female with PCOS and 322 healthy controls, Barnard et al. [10] examined the cognitive function for both groups, in which female with PCOS had impairments in terms of speed, accuracy, and reaction to the role of words. In an investigation on 69 female with PCOS and 41 healthy controls, visual-spatial cognition was measured using a three-dimensional mental rotation tool, and its relationship with the level of sex hormones was examined; female with PCOS showed a higher score on the 3D mental rotation score task than those in the control group. In addition, the level of testosterone in the circulation had a significantly positive correlation with the 3D mental rotation score, but the level of estradiol had an inversely significant correlation with the 3D mental rotation score [38]. However, it should be noted that the electrochemiluminescence method used for the measurement of testosterone in this study might have low sensitivity for the accuracy of detection and may have affected the results of this study. It is also highlighted that this relationship might stem from prenatal androgenization in PCOS. Franik et al. [8] study on 55 female with PCOS indicated an inversely significant relationship between free testosterone (fT) levels and verbal psychomotor speed, suggesting that better verbal psychomotor speed was observed among female with higher fT. Additionally, high androstenedione levels are were associated with a poor level of executive function [8]. It has been showed that androgens act as regulators of amyloid-beta peptide (Aβ) production [39] and Aβ accumulation in the brain is proposed to be an early toxic event in the cognitive alterations such as dementia [40].
In a study involving 22 female with PCOS and 22 healthy female, Schattmann found that verbal memory and fluency, visuospatial working memory, and manual dexterity were worse in female with PCOS than in controls [41]. In this study, higher fT values were associated with lower verbal fluency. In contrast, Kara et al. [42] in their study among 70 adolescents with PCOS, found that mindfulness was not associated with high serum androgen levels [42]. Evidence also suggests that PCOS can affect the function of parts of the brain, reducing face processing and visuospatial working memory. Serum LH levels and LH/FSH ratio are associated with reduced right frontal lobe function in female with PCOS [43]. A possible underlying mechanism is the Aβ. In cases with LH abnormalities, LH promotes the amyloidogenic pathway, eventually leading to cognitive changes [44]. Cognitive function relies on neuronal network interactions and alterations in the hormonal system (steroidal, sexual, and maternal) and can influence cognitive function [45]. There are four phenotypes of PCOS with different hormonal characteristics [46]. It is important to note that the potential effects of hormonal malfunction on cognitive function in female with PCOS may differ between different phenotypes. Hence, the results of these studies remain unconfirmed, and more robust studies should confirm the association between hormonal abnormalities and potential cognitive changes in female with PCOS.

Mood disorder
Studies have indicated that female with PCOS are approximately three and five times more likely to develop depressive and anxiety symptoms, respectively. Those with higher body mass index are also at greater risk of depression and anxiety symptoms [47]. In a study of 53 patients with PCOS and 54 unaffected female, Sukhapure [48] reported that the patient group experienced more depression and cognitive impairment than the other female. High testosterone levels are associated with mood disorders and cognitive dysfunction in verbal and visuospatial learning, memory, psychomotor speed, and emotion processing. Anti-androgen therapy has been associated with improved psychomotor speed and various aspects of emotional processing, and mood improvement is related to improved psychomotor speed, attention, and executive function [48]. A case-control study of 53 female with PCOS and 50 controls aimed at examining the relationship between depression and anxiety and cognitive function in female with PCOS compared with a healthy group indicated that although the PCOS group was more depressed and anxious than the healthy group, there was no significant difference in cognitive functioning between the two groups [49]. Cognitive well-being is closely linked with psychological well-being [50]. Chronic exposure to higher levels of glucocorticoids (GCs) could adversely affect the brain regions responsible for memory and emotions; hence, GCs could contribute to both mental health and cognitive dysfunction [51]. Taken together, further investigations of psychological consultations and their possible impact on cognitive function in female with PCOS are required.

Sleep disorders
Female with PCOS may also develop sleep disorders. Obstructive sleep apnea (OSA) is a common sleep disorder in female with PCOS [52,53] that occurs when the upper airway is partially or entirely blocked, leading to a pause in breathing during sleep [54]. Obesity is a leading risk factor for PCOS and OSA [53]. Cognitive deficits have also been observed in patients with OSA [55]. Subsequent intermittent brain hypoxia with recurrent apneic pauses in patients with OSA can cause structural and cerebrovascular damage to the brain, as well as cognitive impairment [56]. The pathophysiological mechanisms underlying the association between OSA and cognitive impairment include blood–brain barrier disruption, hemodynamic and vascular changes, and intermittent hypoxemia [57]. Furthermore, it is well documented that among female, alterations in estradiol and progesterone levels may be associated with sleep pattern abnormalities and memory problems [58]. Hence, female with PCOS who are at high risk of hormonal abnormalities and sleep disorders might be more prone to cognitive changes.

Acne and cognitive function

PCOS causes dermatological problems, and acne is a symptom of hyperandrogenism [59]. Deveci and Öztürk [60] studied 66 female with acne and 47 controls to assess their cognitive abilities, social phobias, anxiety, and depression. This study showed poorer function in the acne group compared to the control group in terms of cognitive tests assessing attention, verbal episodic memory, working memory, and phonemic verbal mastery [60]. Mehrabadi et al. [61] conducted a study involving 45 female with PCOS and 45 healthy female to investigate the relationship
between acne and cognitive function. A global grading scale for acne was used to examine acne severity and the Montreal cognitive assessment (MoCA) test was used to evaluate cognitive function. The cognitive performance score in the case group was significantly lower than in the control group; however, there was no significant relationship between acne severity and cognitive function [61]. According to the evidence, acne may lead to psychological issues [62,63], and psychological problems may lead to cognitive impairment [64]. The heightened level of psychosocial stress in individuals with psychocutaneous disease affects the hypothalamic-pituitary-axis and contributes to a vicious cycle of worsening disease symptoms [65]. It should be noted that in a study among adolescents with acne, the treatment approach resulted in improvement in neurocognitive functions [66]. Therefore, psychocutaneous therapy may affect cognitive wellbeing. However, there is insufficient data on the impact of acne on cognitive function among female with different PCOS phenotypes.

Metabolic syndrome and cognitive impairment

Metabolic disorders and metabolic syndromes are long-term complications of PCOS and are commonly observed in various PCOS phenotypes [67,68]. Metabolic syndromes can also affect cognitive performance [69]. Lujan and Mergler studied 79 female with PCOS and 40 healthy female, and assessed their cognitive function. The findings showed that female with PCOS have poorer manual dexterity and spatial ability. In the present study, metabolic and reproductive factors predicted cognitive function in female with PCOS [70].
Diabetes and insulin resistance have been identified as mechanisms responsible for cognitive dysfunction. In this regard, a study of Danish female with type 2 diabetes showed that abnormalities in fasting blood sugar were associated with a 44% increase in the likelihood of developing cognitive dysfunction [71]. A study of 353 German subjects with diabetes (type 1 or 2) found that the number of people with verbal memory disorders was significantly higher in patients with type 2 diabetes than in those with type 1 diabetes [72]. Rees et al. [33] conducted a study involving 18 female with PCOS and 18 healthy subjects. They showed that increased insulin resistance was associated with reduced AD in the control group but increased AD in those with PCOS [33].

The research results by Castellano et al. [73] indicated that in female with PCOS, the cerebral metabolic rate of glucose (CMRglu) was 9-14% lower in the frontal, parietal, and temporal cortices. In addition, CMRglu had an inversely significant relationship with HOMA2-IR, which is similar to the pattern observed in aging and Alzheimer’s disease [73]. The role of insulin in the brain of healthy individuals includes the central modulation of metabolism, boosting or regulating memory, and other cognitive and emotional functions. Insulin resistance in the brain can be defined as the failure of brain cells to respond to insulin, which typically disrupts synaptic, metabolic, and immune responses. Type 2 diabetes is associated with insulin resistance in the brain and may play a role in the development of AD [32]. The findings of a study on 40 female with PCOS and 40 healthy female aimed at examining cognitive dysfunction showed that visual-spatial ability was lower in female with PCOS relative to healthy female and that decreasing visual-spatial cognition
was related to hemoglobin A1c levels [74], which are associated with cognitive function [75,76].

Insulin resistance, obesity, hyperlipidemia, and disorders of homocysteine metabolism may be major factors in the development of cognitive impairment in female with PCOS, rather than androgens [77]. A case-control study of 79 female with PCOS and 40 controls revealed that female with PCOS had poorer spatial abilities and manual dexterity scores. The metabolic status and fertility in female with PCOS were predictive of manual dexterity [70]. More robust observational studies and RCTs should address the beneficial effects of controlling metabolic risk factors on cognitive function in female with PCOS in the long term.

Obesity and being overweight are frequent problems in female with PCOS [78]. Cook et al. [79] conducted a study to investigate the relationship between obesity and cognitive impairment in Arab female aged 18-35. This study showed that obese female had significantly lower cognitive functioning and attention, indicating an early disruption of cognitive functioning in obese female [79]. Another study of 110 Chinese male and female aged over 60 years revealed a 1.53-fold increase in cognitive dysfunction with obesity [80]. The mechanism underlying the association between obesity and cognitive dysfunction is unclear; however, it may be related to cerebral atrophy, cerebrovascular disorders, and systemic and central inflammation [81]. Some evidence supports the adverse effects of obesity on cognitive function in female, but the longitudinal impact of obesity and weight gain in female with PCOS is unclear.

A recent study demonstrated that female with PCOS have brain abnormalities at the regional and network levels, and these alterations are associated with serum hormones and cognitive
function [82]. Moreover, a study conducted by Lai et al. [43] on 21 female aged 18-45 with newly diagnosed PCOS, which aimed to investigate the effect of PCOS on brain activity and explore the relationship between brain activity and sex hormone levels in female with PCOS demonstrated that high levels of LH could induce changes in the activity of brain regions responsible for visuospatial working memory, face processing, and episodic memory. In another study, a significant difference was found in the mean grades of acne, hirsutism, total testosterone, free androgen index, depression, anxiety, MoCA as well as in the domains of visual-spatial ability, executive function, and attention in the PCOS group [83]. In addition, higher free testosterone levels in female with PCOS were associated with poorer cognitive function, specifically psychomotor speed and visuospatial learning [84].

Complications or diseases associated with metabolic syndromes, such as hypertension, can also be associated with cognitive impairment. High blood pressure is another complication of PCOS [85,86]. Studies have demonstrated that hypertension disrupts the structure and function of the cerebral blood vessels, leading to ischemic damage to the white matter involved in cognitive function, which may be related to Alzheimer's pathology. There is strong evidence of the destructive effect of hypertension on cognitive function in middle-aged individuals. However, the effect of high blood pressure on cognitive functioning at a later age is less obvious. Observational studies have unveiled the cumulative impact of high blood pressure on cerebrovascular damage. Nevertheless, there is no evidence from clinical trials indicating that antihypertensive therapy can improve cognitive function [87]. The cross-sectional outcome of a review examining the
relationship between high blood pressure and cognitive functioning showed a correlation between blood pressure and cognition, revealing conflicting connections with positive, negative, and J- and U-shaped relationships. Most longitudinal studies have reported that hypertension is associated with diminished cognitive function. A few randomized controlled trials have revealed the heterogeneous effects of lowering blood pressure on cognitive function, suggesting a complex relationship between blood pressure and cognitive function consistent with biological mechanisms [88]. No study has dealt with the relationship between cognitive function and high blood pressure in female with PCOS.

Infertility

Evidence suggests that a history of fertility is a factor that influences the cognitive status of female in later life [89]; therefore, several researchers have found a U-shaped relationship between the number of children and cognitive function in old age [90]. Infertility is a common complication of PCOS [91]. A study involving 830 postmenopausal female in California found that fertility history was linked to cognitive function. Delayed pregnancy after 35 years of age was significantly positively correlated with verbal memory. According to the results of this study, female's reproductive duration has a significantly positive relationship with cognitive function [92]. Meanwhile, the results of a cohort study on postmenopausal female in Latin America and China showed that dementia was not significantly correlated with nulliparity [93]. Another study of 18 female with PCOS and 18 healthy female found partial impairment of cognitive function in female
with PCOS [9]. Female's fertility status is an indicator of estrogen exposure. Cumulative estrogen exposure during reproductive years in female can affect cognitive function [94]. However in female with PCOS, abnormalities in estrogen and estrogen receptors have been observed more frequently [95]. Female with higher parity numbers have a larger gray matter volume, which is linked to cognitive function [96]. Treatment of infertility might influence the cognitive function of female owing to the manipulation of sex hormone levels; however, a study by Leeners et al. [97] did not support the association between high estradiol levels resulting from fertility treatment and cognitive function.

Further studies are required to compare the different aspects of infertility and the number of children in female with PCOS. Additional studies are needed to clarify how many years of infertility could affect cognitive function.

Medications

Metformin and hormone therapy, including oral contraceptives, are treatment options for female with PCOS [98]. A systematic review that examined the findings of 22 studies on the effects of oral contraceptives on cognition showed that contraceptive pills are associated with improved verbal memory. However, depending on the androgenicity, the use of this type of medication and its containing progesterone content could positively or negatively affect visual-spatial cognition [99]. A study of 830 postmenopausal female in California found that hormonal contraceptive pills significantly affected cognitive functioning and verbal memory. Taking contraceptive pills for more
than 10 years boosts verbal memory and executive function [60]. Specialists usually perform symptomatic treatment for PCOS. For example, acne is one of the symptoms usually subject to symptomatic treatment. In a study performed on 55 adolescents; 32 adolescents received antibiotics for acne treatment and another group of 59 received isotretinoin, which indicated improved cognitive function in the group taking isotretinoin [100]. There are no studies of this type in female with PCOS in this respect.

Soleman et al. [101] conducted a study on 40 female with PCOS and hyperandrogenism and 20 healthy female. In this study, cyproterone acetate (25 mg/dL) combined with hormonal OC (35 mg ethinyl E2/d and 2 mg cyproterone acetate, orally) was administered; the intervention group did not receive such treatment, and working memory (speed and accuracy of performance) was measured. The findings of this study revealed that in female with PCOS, all memory conditions related to the parietal (superior and inferior) and temporal (superior) lobes were different from those of the control group. However, there was no difference in performance [101].

A randomized trial was conducted to investigate the effects of hormone treatment on fT levels and cognitive function in female with PCOS. Hormone therapy in female with PCOS significantly reduced their fT levels but did not affect manual dexterity, perceptual speed, visuospatial ability, or verbal memory. However, improved verbal dominance testing scores were observed in female with PCOS compared to their pre-treatment scores. These findings suggest that changes in fT levels do not significantly affect the cognitive function in patients with PCOS [102]. Another study
of 68 female with PCOS and 27 healthy female found that female with PCOS had lower MoCA scores. However, cognition improved after three months of metformin treatment [103].

The limitation of this study is that because of the lack of evidence, we could not determine the exact role of symptoms and markers of PCOS and its related medications in the development of cognitive changes in PCOS patients.

**Conclusion**

In recent years, the incidence of PCOS has increased, resulting in higher disability-adjusted life-years [104]. The underlying pathophysiological mechanisms contributing to the development of PCOS are multifactorial; PCOS is more than one reproductive disorder [105]. As previously mentioned, poor cognitive performance has been observed in individuals with PCOS. However, the exact pathophysiological mechanisms underlying the association between PCOS and cognitive dysfunction remain unknown. PCOS and cognitive dysfunction have been proposed to share common risk factors. PCOS symptoms and comorbidities, such as infertility, appearance changes, cosmetic problems, metabolic disturbances, and sleep problems, could pose the greatest threat to psychological distress in females with PCOS, while psychological distress and cognitive dysfunction are linked together [106,107]. Along with psychological distress, metabolic conditions can contribute to the loss of cognitive function [107]. Moreover, metabolic impairment can affect different aspects of cognitive function, such as executive functioning, visuospatial abilities, and processing speed [108]. Insulin resistance, a prevalent metabolic perturbation in PCOS [105],
connects metabolic syndromes with cognitive impairment [109]. Notably, metabolic disturbances caused by PCOS have discernible effects on metabolic tissues such as the brain [110]. Moreover, brain structure is affected by sex hormone fluctuations. Insulin resistance and hyperandrogenism may result in structural and functional brain disturbances [111].

Despite the seriousness of cognitive impairment in female with PCOS, evidence in this area of research is limited. Considering the existing scientific gap concerning the possibility of cognitive complications in female with PCOS, more biological studies should be conducted to evaluate the potential mechanisms involved. Further studies are required to understand whether there is a relationship between the symptoms and comorbidities of PCOS and poor cognitive function. Overall, recent advances in understanding the etiology and risk factors of cognitive changes in female with PCOS are not comprehensive, and the lack of previous studies in this field represents a gap in knowledge. Identifying similar mechanisms may play a pivotal role in identifying predictive biomarkers of cognitive dysfunction in female with PCOS. Moreover, future research needs to cover the neurobiological and neuroendocrinological aspects of the link between PCOS and cognitive dysfunction.

Evidence shows that disorders related to glucose and insulin may result in poor cognitive function [112]. On the other hand, psychological distress also could affect cognitive function. Female with PCOS may develop either or both. PCOS is complex and heterogeneous; besides the visible reproductive and dermatological aspects of PCOS, silent features should also be considered in the management of patients. Therefore, best management is achieved by a multidisciplinary
care team [113]. Comprehensive psychological assessments and emotional, psychological, and neurocognitive support are essential for the well-being of female with PCOS [114]. Recent guidelines for assessing and managing PCOS have emphasized the critical importance of screening, diagnostic assessment, and treatment for emotional well-being in female with PCOS [115]. Different approaches have been suggested to improve the psychological aspects of PCOS, such as cognitive behavioral therapy, mindfulness, relaxation, guided imagery, and lifestyle modifications [116].

Metabolic screening and brief psychological and cognitive screening in female with PCOS should be considered critical parts of their health care. The ultimate goal of this field is to promote well-being, improve the quality of life of female with PCOS, and reduce the burden of life-threatening disorders, such as dementia and AD.

In the coming years, the increasing prevalence of PCOS and cognitive impairment will become an interesting and key field of research. Future scientific research should focus on predictive biomarkers of cognitive changes in female with PCOS. It is predicted that more observational studies will be conducted to identify knowledge gaps regarding the link between cognitive changes and PCOS. Moreover, there will be a growth in clinical trials to reduce the development of cognitive changes in female with different phenotypes of PCOS within different age groups (adolescents, adults, and menopause).

Optimal diagnosis and improved management of PCOS by improving metabolic and hormonal disorders and decreasing infertility and psychological complications could reduce the risk of
cognitive dysfunction in female with PCOS. Lifestyle interventions such as dietary and exercise interventions, obesity, weight assessment, and behavioral strategies have been suggested as cornerstones in the management of female with PCOS [117]. Nutritional interventions to improve metabolic abnormalities should be advised in female with PCOS. Further clarification on the role of lifestyle modifications in preventing cognitive dysfunction in female with PCOS is necessary. In addition, there will be more studies on the development of molecular tools for diagnosing cognitive changes in female with PCOS and indicating the effect of interventions on reducing cognitive dysfunction or preventing the progression of cognitive changes in female with PCOS over the next 10 years. It is also expected that within the next 5 years, some female with PCOS will undergo cognitive function screening as part of their medical care.

A literature review revealed the possible cognitive changes in female with PCOS. Research has shown that the brain structure is affected by sex hormone fluctuations and metabolic disorders. Therefore, PCOS and cognitive dysfunction may share some common risk factors. Along with significant attention to the fertility aspect of PCOS, a greater focus on cognitive problems in female with PCOS is required.
Conflict of interest

The authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

Ethical approval

This study was approved by the Ethics Committee of the Research Institute for Endocrine Sciences of the Shahid Beheshti University of Medical Sciences.

Patient consent

Funding information

This study received no funding.
References

37. Pessoa L. Emotion and cognition and the amygdala: from "what is it?" to "what's to be done?" Neuropsychologia 2010;48:3416-29.
41. Schattmann L, Sherwin BB. Testosterone levels and cognitive functioning in women with polycystic ovary syndrome and in healthy young women. Horm Behav 2007;51:587-96.
102. Schattmann L, Sherwin BB. Effects of the pharmacologic manipulation of testosterone on cognitive functioning in women with polycystic ovary syndrome: a randomized, placebo-controlled treatment study. Horm Behav 2007;51:579-86.
Possible changes in
- Memory
- Attention
- Executive functioning
- Information processing speed
- Visuospatial skills

Fig. 1. The possible cognition changes related with the polycystic ovary syndrome.
<table>
<thead>
<tr>
<th>Author, yr</th>
<th>Value</th>
<th>Design</th>
<th>Clinical and paraclinical assessment</th>
<th>Cognitive domain</th>
<th>MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sukhapure et al. [84] 2022</td>
<td>PCOS group (n=40), mean age (28.72±7.44); (17-43)</td>
<td>Cross-sectional study</td>
<td>Hormone</td>
<td>Higher free testosterone levels were associated with poorer performance on measures of psychomotor speed (TCT)</td>
<td>-</td>
</tr>
<tr>
<td>Lai et al.</td>
<td>PCOS group</td>
<td>Cross-sectional</td>
<td>Hormone</td>
<td>Higher free testosterone levels were associated with poorer performance on measures of visuospatial learning (GMLT)</td>
<td>LH level can</td>
</tr>
<tr>
<td>Study</td>
<td>Participants</td>
<td>Viscuospatial Activities</td>
<td>Results</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>--------------------------</td>
<td>---------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[43] 2020</td>
<td>(n=21), control group (n=27), mean age: PCO group (25.0±5.0); control group (26.2±2.59)</td>
<td>exhibited increased ALFF value in the left inferior temporal gyrus as well as decreased ALFF value in the left inferior occipital gyrus and the right superior frontal gyrus, which were defined as the three ROI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Li et al. [82] 2020</td>
<td>PCOS group (n=41), control group (n=41), mean age: PCOS group (25.29±3.15); control group (21.8±2.1)</td>
<td>Cross-sectional study</td>
<td>Hormone, insulin resistance, and triglyceride</td>
<td>PCOS group had longer executive control times</td>
<td>There are some changes in regional and network levels of brain function. Female with PCOS had lower score in this domain.</td>
</tr>
<tr>
<td>Mehrabadi et al. [83] 2020</td>
<td>PCOS group (n=53); control group (n=500), mean age: PCOS group (28.47±6.27); control group (29.94±6.24)</td>
<td>Cross-sectional study</td>
<td>Hormone</td>
<td>Female with PCOS had lower score in this domain</td>
<td>Female with PCOS had lower score in this domain</td>
</tr>
<tr>
<td>Barnard et al. 2020</td>
<td>PCOS group (no)</td>
<td>Internet-based study</td>
<td>Hormone</td>
<td>Impaired</td>
<td></td>
</tr>
<tr>
<td>Author(s)</td>
<td>Year</td>
<td>Group Description</td>
<td>Outcome Measure</td>
<td>Research Design</td>
<td>Findings</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>------</td>
<td>-------------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>----------</td>
</tr>
<tr>
<td>al. [10] 2007</td>
<td></td>
<td>AA=112, AA=109;</td>
<td>Mood</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>control group (no</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AA=256, AA=186);</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>mean age: PCOS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>group (no AA=30±6.45, AA=29±5.66); control group (no AA=31±7.61, AA=26±4.32)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barry et al. [38] 2013</td>
<td></td>
<td>PCOS (n=69) and</td>
<td>Cross-sectional</td>
<td>Hormone</td>
<td>Link between visuospatial cognition and sex hormones</td>
</tr>
<tr>
<td></td>
<td></td>
<td>control (n=41);</td>
<td>study</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>mean age: PCOS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(n=29) (18-38),</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>control (n=35)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(24-34)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Castellano</td>
<td></td>
<td>PCOS (n=7) and</td>
<td>Compared study</td>
<td>Insulin</td>
<td>Lower score in 10-17% lower</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Type</td>
<td>Group</td>
<td>Age</td>
<td>Brain Volume</td>
<td>Findings</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>-------</td>
<td>-----</td>
<td>--------------</td>
<td>---------</td>
</tr>
<tr>
<td>et al. [73] 2015</td>
<td></td>
<td>control (n=11)</td>
<td></td>
<td></td>
<td>mean age: PCO=24.6±5.9; control=24.0±3.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>resistance</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>working and episodic memory</td>
</tr>
<tr>
<td>Franik et al. [8] 2019</td>
<td>Case-control study</td>
<td>55 female with PCOS; mean age=24.35±4.164</td>
<td></td>
<td></td>
<td>Hormones and metabolic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Androstenedione level was associated with worse scores in executive</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Higher free testosterone correlated with better verbal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>volume of several brain regions: 10% smaller left superior frontal cortex/ 14% smaller left supramarginal cortex/ 10% smaller right superior parietal cortex</td>
</tr>
<tr>
<td>Jarrett et al. [74] 2019</td>
<td>PCOS (n=40) and control (n=40); mean age: PCOS=27±5, control=27±4</td>
<td>Observational, cross-sectional study</td>
<td>Reproductive and metabolic features</td>
<td>functions</td>
<td>psychomotor speed</td>
</tr>
<tr>
<td>--------------------------</td>
<td>--------------------------------------------------</td>
<td>-----------------------------------</td>
<td>-----------------------------------</td>
<td>-------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Lai et al. [43] 2020</td>
<td>PCOS (n=21) and control (n=27); mean age: PCOS=25±5, control=21.8±2.1</td>
<td>Observational, cross-sectional study</td>
<td></td>
<td>Decreased activities of regions responsible for low-frequency fluctuation (ALFF) in left inferior temporal gyrus and decreased left inferior temporal gyrus</td>
<td>Increased amplitude low-frequency fluctuation (ALFF) in left inferior temporal gyrus and decreased left inferior temporal gyrus</td>
</tr>
<tr>
<td>Study</td>
<td>Group Description</td>
<td>Research Design</td>
<td>Measured Factors</td>
<td>Outcomes</td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------------------------</td>
<td>-----------------</td>
<td>--------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Lujan et al. [70] 2015</td>
<td>PCOS (n=79) and control (n=40)</td>
<td>Case-control</td>
<td>Metabolic and reproductive factors</td>
<td>Lower scores on the mental rotation task on spatial ability</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>study</td>
<td>predictor of spatial ability</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schattmann and Sherwin [102] 2007</td>
<td>PCOS with HRM group [11] and placebo group [8]; mean age: HRM=26.8±6, placebo=26.6±5.2</td>
<td>Randomized, placebo-controlled trial</td>
<td>Hormones and mood</td>
<td>Hormone treatment doesn’t change verbal memory</td>
<td>Hormone treatment doesn’t change manual dexterity, or perceptual speed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hormone treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Design</td>
<td>Sample</td>
<td>Measures</td>
<td>Results</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>--------</td>
<td>----------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>Soleman et al. [101] 2016</td>
<td>Longitudinal study/antiandrogenic hormone treatment</td>
<td>14 female with PCOS and 20 healthy control females/mean age: PCOS=29.3±5.6, control=25.6±6.2</td>
<td>Hormonal</td>
<td>Task performance (speed and accuracy) did not differ between the groups</td>
<td></td>
</tr>
<tr>
<td>D. Aled Rees., 2016</td>
<td>Case-control study</td>
<td>PCOS (n=18) and control (n=18)/mean age: PCOS=31±6, control=31±7</td>
<td>Anthropometric and biochemical measurements</td>
<td>Cognitive performance was degraded in patients</td>
<td></td>
</tr>
</tbody>
</table>

PCOS differed in brain activation in the parietal lobe (superior and inferior) and in the temporal lobe (superior) than control females. Lower value of AD/higher value of tissue volume fraction testosterone level
Sukhapure [48] 2019
PCOS (n=53) and non-PCOS control (n=54) Experimental baseline and 12 weeks after antiandrogen treatment Mood symptoms Correlation between visuospatial learning and memory and worse mood and anxiety Improve in attention by improvement in symptoms of mood Improve in executive function by improvement in symptoms of mood Verbal and visuospatial learning improvement after treatment

Guoqing et al. [17] 2016
PCOS (n=70), 140 controls Case-control Hormones metabolic

Higher prevalence of white matter lesions and silent cerebral
Values are presented as mean±standard deviation or number (%).

PCOS, polycystic ovary syndrome; MRI, magnetic resonance imaging; TCT, full name; GMLT, full name; LH, luteinizing hormone; ALFF, low-frequency amplitude; ROI, region of interest; AA, anti-androgen; HRM, full name; AD, Alzheimer’s disease.